Public Company News
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", "the Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced a glob...
2022-04-07 09:09
2553
Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business
China Resources Pharmaceutical Group ("CR Pharma") intends to make strategic equity investment for Everest's mRNA technology platform Partnership with CR Pharma will provide local support to navigate China regulatory pathways across mRNA vaccine platform, first in the advancement of Everest's po...
2022-04-07 07:30
5004
Denali Capital Acquisition Corp. Announces Pricing of $75 Million Initial Public Offering
NEW YORK, April 6, 2022 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA, the "Company") announced today that it priced its initial public offering ("IPO") of 7,500,000 units at a price of$10.00 per unit. The units have been approved for listing on The NASDAQ Global Market ("NASDAQ"...
2022-04-07 04:41
3806
Sharing Economy and Hanking Fof Investment Signed US$30 Million Investment Cooperation Agreement
HONG KONG, April 6, 2022 /PRNewswire/ -- Sharing Economy International Inc. ("SEII") (OTCQB: SEII), announced today that it has signed an Investment Cooperation Agreement with Hanking Fof Investment, L.P. ("Hanking"). Pursuant to the Agreement, Hanking intends to make strategic investments in SE...
2022-04-06 23:08
4968
HitGen and UPPTHERA Extend PROTAC Research Collaboration after Hit Finding Success on Undruggable Targets
CHENGDU, China, April 6, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STAR-listed company (ticker code 688222.SH), today announced that the company has successfully completed the multiple-target drug discovery research projects with UPPTHERA, a Korean pharmaceutical comp...
2022-04-06 22:30
2909
Nexteer Named a General Motors Supplier of the Year Winner for Third Consecutive Year
AUBURN HILLS, Mich., April 6, 2022 /PRNewswire/ -- Nexteer Automotive, a leader in intuitive motion control, was named a 2021 General Motors Supplier of the Year winner at GM's 30th annual Supplier of the Year awards ceremony. GM's Supplier of the Year award recognizes global suppliers that dis...
2022-04-06 21:36
4555
Noah Holdings Limited Files FY2021 Annual Report On Form 20-F
SHANGHAI, April 6, 2022 /PRNewswire/ -- Noah Holdings Limited ("Noah" or the "Company") (NYSE: NOAH), a leading and pioneer wealth management service provider inChina offering comprehensive one-stop advisory services on global investment and asset allocation primarily for high net worth investors...
2022-04-06 21:27
4478
China Jo-Jo Drugstores, Inc. Announces 1-for-12 Reverse Stock Split
HANGZHOU, China, April 6, 2022 /PRNewswire/ – China Jo-Jo Drugstores, Inc. (" Jo-Jo Drugstores" or the "Company") (Nasdaq: CJJD), a Cayman Islands company, reported that it expects to implement a 1-for-12 reverse stock split on its ordinary shares effectiveThursday, April 7, 2022, with trading to ...
2022-04-06 21:15
4085
Caravelle Group Co., Ltd, an Ocean Technology and Shipping Company, to Become Publicly Traded via Merger with Pacifico Acquisition Corp.
* Caravelle Group Co., Ltd ("Caravelle") is an ocean technology company providing international shipping services and carbon-neutral solutions for wood desiccation. * Caravelle has developed and commercialized its CO-Tech solution, a novel approach toward shipping time, space, and the repurpo...
2022-04-06 21:00
4025
ZEISS to Unveil Clinical Insights Supporting the Value of New Data-Driven Digital Workflow Solutions and Software Applications
Advancing ophthalmic care through integrated clinical workflow solutions: * Efficiency in the cataract workflow * Can help increase treatment outcome predictability in the corneal refractive workflow * Machine learning and artificial intelligence in the retina clinic JENA, Germany and DUBLI...
2022-04-06 21:00
2865
Seegene's Allplex™ RV Master Assay receives Australian TGA approval, European CE-IVD mark
* Test detects 21 targets for 19 respiratory viruses in single tube, including COVID-19 and flu * Assay result of Seegene's decades-long know-how, applies DPO∙TOCE∙MuDT technologies * "Optimal solution for safe return to normalcy as distancing restrictions eased" SEOUL, South Korea, April 6...
2022-04-06 20:08
2876
Antengene's Pivotal "MARCH" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine
- Results showed an overall response rate (ORR) of 29.3% for all treated patients. - Consistent responses across all risk groups, including patients who received prior "triple-class" and CAR-T therapies or having cytogenetic abnormalities. - Selinexor is on track for a Q2:22 launch in China. SHAN...
2022-04-06 20:03
4433
Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process
AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment ofSharon Ballesteros as U.S Head of Quality and Development Process. Sharon has over 20 years of experience within the in vitro d...
2022-04-06 20:00
3819
Quantum Solutions and FOMM to Manufacture First Electric Vehicle for the Japan Market Since Establishing Joint Venture
HONG KONG, April 6, 2022 /PRNewswire/ -- Quantum Solutions (Quantum), the only independent electric vehicle (EV) company listed inJapan, announced that a major shareholder has granted a400-million-yen loan to begin production of its first EV model with its joint-venture partner. This is a crucia...
2022-04-06 17:34
4271
Ascletis Announces China IND Approval of Its Second FASN Inhibitor ASC60 for Treatment of Advanced Solid Tumors
HANGZHOU, China and SHAOXING, China, April 6, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that the Investigational New Drug (IND) application of its second fatty acid synthase (FASN) inhibitor ASC60 for treatment of advanced solid tumors has been approved by China ...
2022-04-06 17:10
4795
Jianpu Technology Inc. to Report Second Six Months and Fiscal Year 2021 Financial Results on Tuesday, April 12, 2022
BEIJING, April 6, 2022 /PRNewswire/ -- Jianpu Technology Inc. ("Jianpu," or the "Company") (NYSE: JT), a leading independent open platform for discovery and recommendation of financial products inChina, today announced that it will report its second six months and fiscal year 2021 unaudited finan...
2022-04-06 17:00
3562
Harbour BioMed Announces Poster Presentation on the Novel Bispecific Antibody PD-L1xCD40 at Upcoming American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced that the poster presenta...
2022-04-06 15:04
3122
Pintec Empowers Wagepay to Upgrade Digital Credit Services
MELBOURNE, Australia, April 6, 2022 /PRNewswire/ -- Pintec Technology Holdings Limited ("Pintec"; NASDAQ: PT), a leading provider of financial technology solutions, today announced that its partner Wagepay Pty. Ltd. (Wagepay), an Australian Pay-on-Demand service provider, has recently launched it...
2022-04-06 13:11
5875
PSMA-PET Imaging to be Funded through Medicare in Australia from July 2022
MELBOURNE, Australia, April 6, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for patients with prostate cancer on the Medicare Benefits Sche...
2022-04-06 12:47
3888
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy
SAN FRANCISCO and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2022-04-06 12:43
4393
Week's Top Stories
Most Reposted
Vietnam: TotalEnergies ENEOS Commissions 28 MWp Rooftop Solar Project at Samsung Electronics HCMC CE Complex
[Picked up by 307 media titles]
2026-07-03 17:10
Traveloka and Marriott International Partner to Bring the World's Leading Hotel Brands Closer to Southeast Asia's Travelers
[Picked up by 302 media titles]
2026-07-02 13:00
InfoComm Asia 2026 - Asia's Super Connector for Professional AV - Takes Place Next Week in Bangkok
[Picked up by 295 media titles]
2026-07-07 09:00
PropertyGuru Group's 2025 Sustainability Report Reinforces its Commitment to More Resilient and Inclusive Urban Futures Across Southeast Asia
[Picked up by 288 media titles]
2026-07-08 12:09
Gene Solutions' SPOT-MAS 10 Places Asia-Led Cancer Screening Innovation in the Global Spotlight
[Picked up by 283 media titles]
2026-07-07 06:00
Most Read
JINRO, the World's No. 1 Soju Brand, Partners with V of BTS
2026-07-03 08:00
20076
/C O R R E C T I O N -- Nuvei/
2026-07-02 23:01
9896
China Yuchai International to Pay US$0.87 Per Share Cash Dividend for FY2025
2026-07-02 20:38
9249
NYSE Content Update: Sail4th 250 Gears Up for Historic Tall Ships Parade
2026-07-02 21:26
8686
